Dr. Estes was invited to speak at the Orthopaedic Manufacturing & Technology Exposition and Conference Tech Center on June 14, 2017. Dr. Estes presented a review of functional tissue engineering methods and novel approaches to regenerate and repair diseased cartilage along with an overview of advancements in stem cell research.
Dr. Vince Willard recently co-authored two papers studying applications of gene editing of stem cells to prevent inflammation. One paper, entitled “CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues,” published in the May 2017 edition of Arthritis & Rheumatology. The other paper, “Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop […]
Cytex’s intellectual portfolio is further strengthened with the most recent US patent continuation, “Tissue Engineering Methods and Composition,” Patent No.: US 9,649,409 B2 on May 16, 2017.
Cytex is excited to receive a Phase 2 STTR award from NIH to fund a project “Unicondylar Resurfacing in Ovine Osteoarthritis”. This study examines the efficacy of Cytex’s cartilage resurfacing implant in an ovine knee model.
Dr. Willard was invited to speak at the 2017 Orthopaedic Research Society annual meeting February 19, 2017. Dr. Willard presented the results of a study entitled “The Mechano and Osmosensitive Ion Channel TRPV4 and How it Serves as a Functional Regulator of iPSC Chondrogenesis.”
Cytex is proud to have Dr. Farsh Guilak preside over the 2017 meeting of the Orthopaedic Research Society in San Diego on March 19th through 22nd, 2017. In addition to serving as president of Cytex Therapeutics, Dr. Farsh Guilak is Professor of Orthopaedic Research and the Co-Director of Regenerative Medicine at Washington University, and one of […]
An image from Cytex’s research on its proprietary implant was featured on the December 2016 cover of Bonezone, an Orthoworld publication focused on commercialization solutions for the orthopedic industry.
Cytex’s 3-D weave technology is featured as this fall’s cover image on the Regenerative Medicine issue of Breakthroughs in Bioscience, a journal highlighting scientific breakthroughs important to society. The publication is produced by Federation of American Societies for Experimental Biology (FASEB), the nation’s largest coalition of biomedical researchers.
Cytex is thrilled to receive an award from NIH to fund strategic regulatory and manufacturing planning to accelerate the commercialization of its products. The grant awarded is part of the pilot Commercialization Readiness Program offered to recipients of NIH Phase II SBIR/STTR awards.
Cytex is delighted to be awarded entry to the highly successful Commercialization Acceleration Program offered as a competitive award to recipients of NIH Phase II SBIR or STTR awards. The program provides training and support for Cytex staff in commercialization activities such as regulatory planning, investment negotiations, and product marketing.